Clinicopathologic, genomic and protein expression characterization of 356 ROS1 fusion driven solid tumors cases

MAPK pathway alterations correlate with poor survival and drive resistance to therapy in patients with lung cancers driven by ROS1 fusions

(2020) Hiroki Sato et al.   CLINICAL CANCER RESEARCH

Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry Biomarkers in 312 Patients with Breast Cancer

(2020) Richard S.P. Huang et al.   ONCOLOGIST

Resistance mechanisms and potent-targeted therapies of ROS1-positive lung cancer

(2019) Annie Roys et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

ROS1-rearranged NSCLC With Secondary Resistance Mutation: Case Report and Current Perspectives

(2019) Florian Guisier et al.   Clinical Lung Cancer

A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability and Pan-Tumor Characterization of 1000 Microsatellite Instability–High Cases in 67,000 Patient Samples

(2019) Sally E. Trabucco et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials

(2019) Alexander Drilon et al.   LANCET ONCOLOGY

Recent Advances in Targeting ROS1 in Lung Cancer

(2017) Jessica J. Lin et al.   Journal of Thoracic Oncology

ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non–Small Cell Lung Cancer

(2017) Jessica J. Lin et al.   Journal of Thoracic Oncology

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

(2017) Ahmet Zehir et al.   NATURE MEDICINE

Concurrent ROS1 gene rearrangement and KRAS mutation in lung adenocarcinoma: A case report and literature review

(2017) You-cai Zhu et al.   Thoracic Cancer

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

(2017) Zachary R. Chalmers et al.   Genome Medicine

ROS1fusions in cancer: a review

(2016) Arnaud Uguen et al.   Future Oncology

An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer

(2016) Rafal Dziadziuszko et al.   Journal of Thoracic Oncology

Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer

(2015)   NEW ENGLAND JOURNAL OF MEDICINE

Activation of RAS family members confers resistance to ROS1 targeting drugs

(2015) Marilisa Cargnelutti et al.   Oncotarget

Multiple hypothesis testing in genomics

(2014) Jelle J. Goeman et al.   STATISTICS IN MEDICINE

Molecular Pathways: ROS1 Fusion Proteins in Cancer

(2013) K. D. Davies et al.   CLINICAL CANCER RESEARCH

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing

(2013) Garrett M Frampton et al.   NATURE BIOTECHNOLOGY

Novel Targets in Non-Small Cell Lung Cancer: ROS1 and RET Fusions

(2013) J. F. Gainor et al.   ONCOLOGIST

Analysis of Receptor Tyrosine Kinase ROS1-Positive Tumors in Non-Small Cell Lung Cancer: Identification of a FIG-ROS1 Fusion

(2012) V. M. Rimkunas et al.   CLINICAL CANCER RESEARCH

ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers

(2012) Kristin Bergethon et al.   JOURNAL OF CLINICAL ONCOLOGY

Spectrum of Oncogenic Driver Mutations in Lung Adenocarcinomas from East Asian Never Smokers

(2011) Chenguang Li et al.   PLoS One